Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
grade B 143.28 1.39% 1.97
BGNE closed up 1.39 percent on Friday, January 18, 2019, on 40 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical BGNE trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Multiple of Ten Bullish Other 1.39%
Jan 17 Outside Day Range Expansion 1.39%
Jan 17 Overbought Stochastic Strength 1.39%
Jan 16 NR7 Range Contraction 1.75%
Jan 16 Multiple of Ten Bullish Other 1.75%

Older signals for BGNE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Is BGNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 220.1
52 Week Low 105.19
Average Volume 691,361
200-Day Moving Average 158.336
50-Day Moving Average 134.5814
20-Day Moving Average 136.177
10-Day Moving Average 140.736
Average True Range 7.9649
ADX 8.58
+DI 20.8619
-DI 20.9323
Chandelier Exit (Long, 3 ATRs ) 120.8453
Chandelier Exit (Short, 3 ATRs ) 131.8947
Upper Bollinger Band 149.455
Lower Bollinger Band 122.899
Percent B (%b) 0.77
BandWidth 19.50109
MACD Line 2.1856
MACD Signal Line 1.4554
MACD Histogram 0.7303
Fundamentals Value
Market Cap 5.71 Billion
Num Shares 39.8 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -28.83
Price-to-Sales 0.00
Price-to-Book 12.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 148.26
Resistance 3 (R3) 147.83 145.73 147.43
Resistance 2 (R2) 145.73 144.47 145.95 147.15
Resistance 1 (R1) 144.51 143.68 145.12 144.94 146.88
Pivot Point 142.41 142.41 142.72 142.63 142.41
Support 1 (S1) 141.19 141.15 141.80 141.62 139.68
Support 2 (S2) 139.09 140.36 139.31 139.41
Support 3 (S3) 137.87 139.09 139.13
Support 4 (S4) 138.30